

# CUMULATIVE INDEX 1996

## Volume 12

---

February	CORONARY ARTERY DISEASE IN THE ELDERLY, pages 1-236
May	CARE OF THE TERMINALLY ILL PATIENT, pages 237-433
August	PAIN MANAGEMENT, pages 435-633
November	GAIT AND BALANCE DISORDERS, pages 635-902

---

Note: Page numbers of article titles are in **boldface** type

- Abdominal pain, as reason for physician visit, 445
- Academy of Hospice Physicians, 263
- Acceptance, in dying process, 361
- Accidental falls, in nursing home, 885-886
- Acetaminophen, for cancer pain, 287-288
- Active euthanasia, definition of, 624
- moral issues of, 625-626
- near end of life, 373-374
- patient requests for, 624-625
- with pain, 623-626
- Acupuncture, for pain management, in terminal care, 303-304
- Acute myocardial infarction, therapy for, **141-168**. See also *Myocardial infarction*.
- Adenosine, for pharmacologic stress testing, 113
- Advance directives, in end of life decision making, 372-373
- Aerobic capacity, changes with aging, 81
- Aerobic conditioning, interventions and outcomes with, 770-771
- studies of, 769-772
- in healthy elders, 769-772
- in impaired elders, 771-772
- Aerobic exercise, recommendations for, 216
- Age(ing), decline in fitness with, 210-211
- decline in function with, 209-210
- effect on exercise capacity, 102
- effect on maximal heart rate, 102-103
- effects on biomechanics and physiology of gait, **659-678**
- hypertension and, common features of, 45
- normal, pain in, 461-462
- physiologic decline with, and cardiac disease, 208-211
- Agonists, opioid, 490, 492-495. See also *Opioid(s)*.
- Alarm systems, for fall prevention, in nursing home, 897
- Allodynia, with nerve injury, 503
- Alpha, agonists, for neuropathic pain, 512
- Alpha blockers, for left ventricular hypertrophy, 64
- Alzheimer's disease. See *Cognitive impairment; Dementia*.
- Ambulacrum, for fall prevention, in nursing home, 897
- Ambulatory electrocardiography, in myocardial infarction diagnosis, 93-97
- Amitriptyline, adjuvant, for cancer pain, 295
- for neuropathic pain, 508
- Amsler grid, for central visual field evaluation, 813-814
- Analgesics, administration of, routes for, 495
- for neuropathic and sympathetically maintained pain, **501-515**
- for postoperative pain management, 586-594
- narcotics, 588-594
- nonsteroidal anti-inflammatory drugs, 586-588
- opioid, in elderly, **489-500**. See also *Opioid(s)*.
- pain clinic use of, 567
- Anesthetic procedures, for back pain management, 522-523
- Anger, in dying process, 360
- Angina, as reason for physician visit, 444
- in coronary artery disease, 89-91, **121-140**
- stable, drug treatment of, 132-134
- unstable, coronary angiography for, 136
- management of, 134-137
- pathogenesis of, 134
- with hypertension, 47

- Angiotensin-converting enzyme (ACE) inhibitors, after acute myocardial infarction, 172-174  
 for acute myocardial infarction, 150-151  
 for atherosclerotic lesions, 14  
 for hypertension, 49  
 for hypertension prevention, 51-52  
 for left ventricular hypertrophy, 64
- Anisoylated plasminogen streptokinase activator complex (APSAC), for acute myocardial infarction, 147-148
- Ankle, gait kinetics of, 672  
 kinematics of, 667-668, 670
- Antiadrenergic drugs, peripherally acting, for hypertension prevention, 52
- Antiarrhythmic agents, for acute myocardial infarction, 151-152
- Anticholinergics, for dyspnea, in terminal illness, 318
- Anticoagulant(s), after acute myocardial infarction, 174-175  
 for acute myocardial infarction, 149  
 for unstable angina, 136
- Anticonvulsants, adjuvant, for cancer pain, 294-296  
 for neuropathic pain, 510
- Antidepressants, adjuvant, for cancer pain, 294-296  
 and falls, 850-851  
 for neuropathic pain, 507-510  
 in terminal illness, for anxiety, 332  
 for depression, 334
- Antiemetics, dosages of, in terminal illness, 316
- Antihypertensive treatment, and falls, 851-852  
 benefit in very old, 48  
 in primary and secondary prevention, 50-53
- Antiviral agents, for neuropathic pain, 512-513
- Anxiety, in terminal illness, 330-333
- Anxiolytic medications, for terminally ill patients, 331
- Arm movements, compensatory, control of, 649-653
- Aromatherapy, for pain management, in terminal care, 306-307
- Arrhythmia(s), in acute myocardial infarction, management of, 155-156  
 in coronary artery disease, 89-91  
 in myocardial infarction diagnosis, 94  
 in myocardial infarction prediction, 94, 95
- Arterial compliance, decreased, in hypertension, 44-46
- Arthralgia, as reason for physician visit, 444
- Arthritis, and pain, in nursing home, 602  
 and risk of fall, treatment of, 755  
 as reason for physician visit, 444
- Aspirin, after acute myocardial infarction, 174  
 for acute myocardial infarction, 143-144  
 for coronary heart disease prevention, in diabetes mellitus, 75
- Assisted suicide, with pain, 623-626. See also *Suicide*.
- Atenolol, for acute myocardial infarction, mortality in, 144
- Atherosclerosis, and diabetes mellitus, as cardiovascular disease risk factors, 70-71  
 lesions of, future approaches to, 13-15  
 initiation of, 1-2  
 morphology of, 4  
 progression of, 2-11  
   plaque rupture and occlusive thrombus formation, 7-10  
   rapid thrombus-mediated, 7  
   slow, 3-5  
   stable collagen-rich plaque formation, 11  
   unstable lipid-rich plaque formation, 5-7  
 regression of, 13-15  
 thrombogenic factors in, local, 8-9  
   degree of plaque disruption, 8  
   degree of stenosis, 8-9  
   residual thrombus, 9  
   surface roughness, 9  
   tissue substrate, 8  
 systemic, 9-10  
   cholesterol levels, 9-10  
   enhanced coagulation activity, 10  
   enhanced platelet activity, 10  
   high catecholamine levels, 9  
   high Factor VII levels, 10  
   high fibrinogen levels, 10  
   impaired fibrinolysis, 10  
   lipoprotein(a) levels, 9-10  
   metabolic state, 9-10  
   vulnerability to rupture, 6-7
- Attention-diversion techniques, in pain management, 466
- Attention span, with aging, 467
- Autonomy, cultural differences concerning, 399-400  
 cultural perspectives on, 397-399  
 in pain management, 621
- Back pain, as reason for physician visit, 443
- Baclofen, for neuropathic pain, 512
- Balance. See also *Gait*.  
 control of, during gait and volitional movement, 653-654  
 definition of, 706  
 disorders of, in Parkinson's disease, 825-845  
 clinical manifestations of, 825-827

- laboratory studies of, 828-838
- functional assessment of, 705-723
  - evaluation framework for, 719-720
  - existing measures for, 710-718
  - practicality of, 710
  - properties and potential uses of, 717-718
  - rationale for, 706-708
  - reliability and validity of, 708-709
  - responsiveness of, 709-710
- in gait, 662-664
- interventions and outcomes with, in healthy elders, 774
- problems with, and risk of fall, treatment of, 755
- studies of, 772-773
- Balance function, assessment of, in dizziness, 797
- Balance Scale, for functional balance and gait measures, 717
  - reliability of, 711-712
  - responsiveness of, 712
  - validity of, 713
- Bargaining, in dying process, 360-361
- Base of support, definition of, 636
- Bedcheck, for fall prevention, in nursing home, 897
- Behavior, as evidence of pain, in cognitively impaired persons, 484
- Behavior modification, for pain management, in terminal care, 305-307
  - aromatherapy, 306-307
  - guided imagery, 305-306
- Behavioral-cognitive techniques, in pain management, 464-466
- Beneficence, in pain management, 621
- Benzodiazepine(s), and falls, 850-851
  - in terminal illness, for anxiety, 330-332
  - for depression, 340
  - for dyspnea, 318
- Bereavement care, in terminal illness, 273-277
  - age-appropriate models and interactional styles, 276-277
  - intervention in abnormal grief process, 276
  - progress of grief process, 274-276
  - use of medications, 274
  - validate and normalize feelings, 274
- Best interests, definition of, 377
- Beta blocker(s), after acute myocardial infarction, 169-171
  - for acute myocardial infarction, 144-146
  - contraindications to, 146
  - mortality in, 144-145
  - for angina, 127-130
    - adverse reactions to, 129-130
    - antiarrhythmic properties of, 129
    - lipid solubility of, 127, 129
    - pharmacology of, 128
    - sympathomimetic properties of, 129
    - types of, 127
  - for atherosclerotic lesions, 14
  - for hypertension, 49
  - for hypertension prevention, 50
  - for left ventricular hypertrophy, 63
  - for unstable angina, 136
  - with calcium channel blocker, for stable angina, 133
  - with nitroglycerin, for stable angina, 133
- Bile acid sequestrants, as lipid-lowering agents, 37
- Bioethics, in pain management, 619-621
- Blind spot, paracentral, effect of, 807
- Blood pressure, effect of physical activity on, 80
- Body, disposal of, customs related to, 396-397
- Body composition, decline with aging, 210
- Body fat distribution, effect of physical activity on, 80
- Body weight, effect of physical activity on, 80
- Bone pain, adjuvant treatment for, 296
- Bowel obstruction, in terminal illness, clinical features of, 323
  - management of, 322-324
- Bowel regimens, for constipation, in terminal illness, 321
- Bradykinesia, in Parkinson's disease, 834
- Breathing pattern change, in impending death, 364
- Buprenorphine, for postoperative pain management, 589
- Bupropion, for depression, in terminal illness, 338
- Bursitis, as reason for physician visit, 445
- Calcium channel blocker(s), after acute myocardial infarction, 171-172
  - for acute myocardial infarction, 150
  - for angina, 130-132
  - for hypertension, 49
  - for hypertension prevention, 50-51
  - for left ventricular hypertrophy, 64
  - with long-acting nitrate, for stable angina, 133
- Cancer pain, analgesics for, 285-296
  - non-opioids, 285-287
    - acetaminophen, 287-288
    - dosing of, 287
    - nonsteroidal anti-inflammatory drugs, 285-287
    - tramadol, 288
  - opioids, 288-292. See also *Opioids*.
  - assessment of, 283-284
  - causes of, 283
  - in nursing home, 602
  - incidence and impact of, 280-281

- Cancer pain (*continued*)  
 management of, ethical issues in, 617  
 initial strategies for, 611  
 pharmacologic management of, 284-285  
 treatment of, 280  
 types of, 283-285  
 undertreatment of, factors contributing to, 282
- Capacity, definition of, 377
- Capsaicin, adjuvant, for cancer pain, 295  
 for neuropathic pain, 511
- Captopril, after acute myocardial infarction, 172
- Carbamazepine, adjuvant, for cancer pain, 295
- Cardiac disease, exercise training for, outcomes of, 223-226  
 physiologic decline with aging and, 208-211
- Cardiac events, major, with left ventricular hypertrophy, 61-62
- Cardiac rehabilitation, exercise training and, goal of, 213  
 guidelines for, 221-224
- Cardiogenic shock, in acute myocardial infarction, management of, 157-158
- Cardiomyopathy, diabetic, 74
- Cardiorespiratory endurance, decline with aging, 210
- Cardiovascular changes, with exercise training, 211-212
- Cardiovascular disease, dyslipidemia and, 33  
 prevention of, cholesterol lowering and, 36  
 risk of, factors in, 70-71  
 lipoprotein disorders as predictors of, 34-35
- Cardiovascular function, assessment of, in dizziness, 796  
 physiologic decline with aging, 208-209
- Caregiver, concerns about home pain management, 538  
 involvement in pain management, 531-547  
 nonfamilial, involvement of, 541  
 pain experience of, 537  
 roles of, in nondrug pain relief, 538-539  
 in pain management, 536-538
- Catecholamines, high levels of, in atherosclerotic thrombogenesis, 9
- Causalgia, with traumatic nerve injury, 503-504
- Celiac plexus block, for pain, 553-555
- Center of mass, definition of, 636  
 displacement of, plots of, 662
- Center of pressure, changes with aging, technology-based assessment of, 729  
 definition of, 636
- Central nervous system depressants, for neuropathic pain, 506-507
- Central pain, 505
- Cerebrovascular disease, postural control and gait assessment in, 735
- Cervical dizziness, 792
- Chest pain, in myocardial infarction, 92
- Chlorpromazine, for anxiety, in terminal illness, 332
- Cholesterol, elevated, and coronary disease risk, 35  
 levels in atherosclerotic thrombogenesis, 9-10  
 lowering of, and cardiovascular disease prevention, 36  
 special considerations in elderly, 36-38
- Clonidine, for neuropathic pain, 512
- Coagulation activity, enhanced, in atherosclerotic thrombogenesis, 10
- Codeine, as opioid agonist, 492-493  
 for cancer pain, 291
- Cognitive-behavioral therapies, in pain management, 465-466, 523-524
- Cognitive changes, with aging, implications for treatment, 469
- Cognitive impairment, and falls, in nursing home, 886  
 and inadequate pain management, 585  
 and risk of fall, treatment of, 755  
 as barrier to pain assessment, 610  
 in late life, epidemiology of, 474-475  
 in terminal illness, 340-344  
 increase with aging, 474  
 pain with, 473-487
- Cognitive status, in nursing home population, 476
- Cognitive therapy, in pain management, 465-466, 523-524
- Cold, as pain inducer, effects of, 439
- Collateral circulation, role of, in coronary plaque evolution, 12-13
- Communications, unusual, with impending death, 365
- Community settings, supportive, creation of, for falls prevention, 874-875
- Competence, definition of, 377
- Comprehensive care, in terminal illness, 270-277. *See also* *Terminal illness*.
- Compression fracture, pain syndrome in, 525-526
- Conduction disturbances, in acute myocardial infarction, management of, 155-156
- Confrontation tests, for visual field evaluation, 813
- Congestion, in impending death, 364
- Congestive heart failure, in acute myocardial infarction, management of, 153-154

- Constipation, in terminal illness, causes of, 320  
     management of, 319-321  
     with opioids, 497
- Contrast, calculation of, 807  
     sensitivity to, and mobility, 806-811  
         calculation of, 809  
         curve of, 809  
         normal vs abnormal, 811  
         loss of, 804  
         measurement chart for, 810
- Control, feedback, definition of, 636  
     feedforward, definition of, 636  
     postural, 635-658. See also *Postural control*.
- Coolness, in impending death, 363
- Cordotomy, for pain management, in terminal care, 309
- Coronary angioplasty, percutaneous transluminal, 181-194  
     bypass surgery vs, 185-187, 202-203  
     mortality rate, 186  
     patient selection, 188  
     predictors of outcome, 186-187  
     stroke and cognitive dysfunction, 186  
     characteristics of elderly receiving, 182  
     completeness of revascularization, 184-185  
     for acute myocardial infarction, 152-153, 187-188  
     for chronic coronary artery disease, 181-185  
     goals of therapy with, 189  
     intracoronary stents in, 188  
     long-term outcome after, 184  
     predictors of poor early outcome, 183  
     procedural outcome of, 182-183
- Coronary artery bypass surgery, 195-205  
     evidence of benefit of, 200-202  
     goals of treatment with, 196  
     hospital stay following, 199  
     indications for, 197-198  
     long-term survival following, 200-202  
     percutaneous transluminal coronary angioplasty vs, 185-187, 202-203  
     perioperative morbidity and mortality with, 198-200  
     risk factors in, 199
- Coronary artery (heart) disease, angina in, management of, 121-140  
     drug therapy for, 122-132  
         nitrates, 123-125  
         general measures, 121-122  
     chronic, percutaneous transluminal coronary angioplasty for, 181-185  
     clinical manifestations of, 89-100  
     diabetes mellitus and, 69-78. See also *Diabetes mellitus*.  
     diagnosis of, 46, 89-100
- dyslipidemia and, 33-40. See also *Dyslipidemia*.
- exercise training for, 207-229. See also *Exercise training*.
- hypertension and, 41-56. See also *Hypertension*.
- mortality with increasing age, 34
- pathophysiology of, 1-21
- physical inactivity and, 79-88. See also *Physical activity*.
- smoking and, 23-32. See also *Smoking*.
- stress testing for, 101-119. See also *Stress testing*.
- with aging, 211
- Coronary perfusion, decreased, with left ventricular hypertrophy, 59
- Coronary plaques, evolution of, clinical consequences of, 11-13  
     coronary syndromes, 11-12  
     role of vasospasm and collateral circulation, 12-13
- Coronary syndromes, in coronary plaque evolution, 11-12
- Corticosteroids, adjuvant, for cancer pain, 295  
     in terminal illness, for bowel obstruction, 324  
     for dyspnea, 318
- Cost-effective hospice care, 417-428
- Cough, in terminal illness, management of, 318-319
- Coumadin, after acute myocardial infarction, 174-175
- Cruciform anterior spinal hyperextension orthosis, for back pain management, 522, 525
- Cryotherapy, in pain management, 521
- Cultural considerations, involving death and dying, 393-406  
     as barriers to effective palliative care, 412-414  
     "blind spots", 399-401  
     faux pas, 395  
     insensitivity, 395-397  
     misunderstandings, 397-399  
     strategies for, 402-405
- Dark adaptation, and mobility, 811
- Deafferentiation pain, 505
- Death, and dying, 359-368  
     perspectives on, 359-362  
     stages of, 360-361  
     approach of, recognition of, 359-368  
     appropriate, 361-362  
     care for survivors, 367  
     cultural considerations of, 393-406  
     "blind spots", 399-401  
     faux pas, 395  
     insensitivity, 395-397

- Death (*continued*)
- misunderstanding, 397-399
  - strategies in, 402-405
    - comfortable setting, 403
    - cultural guides, 404-405
    - eliciting cultural information, 404
    - patient-directed disclosure, 403-404
    - recognition of one's own cultural beliefs/biases, 403-404
  - technology and changes, 401
  - epidemiology of, 255-256
  - location of, 362
  - relevance of culture to, 393-394
- Decision making, capacity for, establishment of, 370-371
- ethical, near end of life, 369-377
- advance directives, 372-373
  - futility, 374
  - justice, 374-375
  - surrogate, 373
  - therapeutic privilege in, 371-372
  - voluntary active euthanasia, 373-374
- Delirium, and inadequate pain management, 585
- in terminal illness, 341
    - causes of, 342
    - medications for, 343
  - increase with aging, 469
- Dementia, epidemiology of, 474
- increase with aging, 468
  - syndrome of depression with, increase with aging, 468-469
  - transition to terminal care in, 354-355
- Denial, in dying process, 360
- Depression, and pain, in nursing home, 609-610
- dementia syndrome of, increase with aging, 468-469
  - in terminal illness, 333-340, 361
  - with pain, 464
- Dextorphan, for neuropathic pain, 513
- Dextroamphetamine, for depression, in terminal illness, 338
- Diabetes mellitus, and coronary heart disease, 69-78
- and coronary risk, 72-73
  - as cardiovascular disease risk factor, 70-71
  - atherogenesis in, 71
  - glucose tolerance and, 69-70
  - management in elderly, 74-76
- Diabetic cardiomyopathy, 74
- Diabetic retinopathy, contrast sensitivity curve in, 811
- Diagnostic blocks, for pain diagnosis and treatment, 549-550
- Diarrhea, in terminal illness, management of, 321-322
- Diazepam, and falls, 852
- Dihydropyridines, for angina, 131-132
- Diltiazem, after acute myocardial infarction, 171-172
- and falls, 852
  - for angina, 132
- Dipyridamole, for pharmacologic stress testing, 113
- Disability, definition of, 762
- Disease, definition of, 762
- Disorientation, in impending death, 363
- Distress, with pain, 464
- Diuretics, and falls, 852
- for hypertension prevention, 50
  - for left ventricular hypertrophy, 63
- Dizziness, and falls, in nursing home, 885
- approach to patient with, 795-798
  - history, 795-796
  - physical examination, 795-796
  - psychological status assessment, 797
  - clinical classification of, 787-788
  - evaluation and management of, 785-801
  - key syndromes of, 789-794
    - cervical, 792
    - drug-induced, 793
    - labyrinthitis, 790
    - Meniere's disease, 790
    - multiple neurosensory impairments, 793-794
    - physical deconditioning, 792-793
    - positional vertigo, 789-790
    - postural dizziness without postural hypotension, 789
    - psychologic factors, 794
    - recurrent vestibulopathy, 790
    - stroke, 791-792
    - vertebrobasilar transient ischemic attacks, 791
    - vestibular neuritis, 790
  - management of, 798-799
  - pathophysiology of, 788-789
  - symptoms of, 786-788
- Dobutamine, for pharmacologic stress testing, 114
- Dorsal column stimulation, for pain, 556-557
- Dorsal rhizotomy, for pain management, in terminal care, 309
- Drop attacks, and falls, in nursing home, 886-887
- Drug(s), and falls, in nursing home, 887
- Drug-induced dizziness, 793
- Duke Mobility Scale, 713
- for functional balance and gait measures, 718
- Dying, cultural considerations of, 393-406
- "blind spots", 399-401
  - faux pas, 395
  - insensitivity, 395-397
  - misunderstanding, 397-399
  - strategies in, 402-405. See also under *Death*.

- technology and changes, 401
- end-of-life opportunities with, 244-251
  - developmental model of, 247-249
  - life review, 249-250
  - meaning and the transcendent, 250-251
- epidemiology of, 255-256
- hospice approach to, 239-240, 254
- mental and spiritual changes in, 364-365
- patient care in, 253-265
  - physical symptoms and, 362-364
  - predicting terminal diagnosis in, 261-262
  - relevance of culture to, 393-394
- Dynamic equilibrium, definition of, 636
- Dysequilibrium, clinical classification of, 786
  - definition of, 786
  - of aging, 788
- Dyslipidemia, after acute myocardial infarction, management of, 175-176
  - and coronary artery disease, 33-40
- Dyspnea, in coronary artery disease, 89-91
  - in myocardial infarction, 92
  - in terminal illness, management of, 316-318
- Dysrhythmias, with left ventricular hypertrophy, 60-61
- Echocardiographic exercise testing, 113
- Echocardiography, in myocardial infarction diagnosis, 97-98
- Electrical shock, as pain inducer, effects of, 439
- Electrocardiography, abnormalities with hypertension, 47
  - ambulatory, in myocardial infarction diagnosis, 93-97
  - exercise, prognostic utility of, 105-109
  - resting, for myocardial infarction diagnosis, 92-93
- Electrotherapy, pain clinic use of, 569
- Emetic brain areas, characteristics of, 314
- Enalapril, after acute myocardial infarction, 173
- Enalaprilat, after acute myocardial infarction, 172-173
- End of life, developmental tasks and landmarks for, 248
  - ethical decision making near, 369-377
  - opportunity at, nature of, 237-252
    - developmental model of, 247-249
    - life review, 249-250
    - meaning and the transcendent, 250-251
- Environment, and falls, in nursing home, 867, 869, 885-886
  - role in falls prevention, 859-880
  - supportive, creation of, for falls prevention, 874-878
- barriers to safety modifications, 875-878
  - use as instrument for change, 859-869
- Environmental press, excess disability with, 872
- Equilibrium, dynamic, definition of, 636
  - impaired control of, in Parkinson's disease, 836-837
- Estrogen replacement, after acute myocardial infarction, 177-178
  - for hypertension prevention, 52-53
- Ethical decision making, near end of life, 369-377
- Ethical issues, in pain management, 615-628
- Ethyl alcohol neurolysis, for pain, 555-556
- Euthanasia, definition of, 624
  - moral issues of, 625-626
  - patient requests for, 624-625
  - voluntary active, near end of life, 373-374
  - with pain, 623-626
- Excess disability, with environmental press, 872
- Exercise, cardiovascular response to, 101-103
  - combined, interventions and outcomes with, in healthy elders, 775-776
    - in impaired elders, 777
  - studies of, 773-779
    - in healthy elders, 773-779
    - in impaired elders, 779
  - for postural control and gait, technology-based assessment of, 736-737
  - injury during, incidence by age and activity, 219
  - interventions with, positive effects of, 780-781
  - pain clinic use of, 568-569
  - progressive, for back pain management, 522
- Exercise testing, diagnostic value of, 103-104
  - echocardiography, 113
    - for myocardial infarction diagnosis, 93
  - radionuclide, diagnostic utility of, 109-110
    - prognostic utility of, 110-113
- Exercise training, and cardiac rehabilitation, goal of, 213
  - components of, 215, 218
  - for coronary artery disease, 207-229
  - guidelines for, 214
    - cardiac rehabilitation, 221-224
    - healthy asymptomatic elderly, 218-221
    - healthy young and middle-aged, 214-218
    - in cardiac disease, 215, 224
  - in cardiac disease, outcomes of, 223-226
  - physiologic responses to, 225
  - prescription for, 214-226



Exercise training (*continued*)

- intensity, frequency, and duration of, 214-217
- outcome of, 211-213
  - cardiovascular changes, 211-212
  - health changes, 212-213
  - musculoskeletal changes, 212
- progression of training stimulus, 217-218, 220
- resistance, 220
- Exertion, perceived, Borg scales for, 216
- Extremity weakness, and risk of fall, treatment of, 755
- Facial expression, as evidence of pain, in cognitively impaired persons, 483
- Factor VII levels, in atherosclerotic thrombogenesis, 10
- Fall(s), among community residents, environmental factors in, 860, 865
  - conditions for, 638
  - environmental risk factors in, circumstances, 861-864
    - inadequate conceptualization, 870
    - measurement of, 871
    - mechanisms of, 871
  - frequent, in Parkinson's disease, 827
  - history of, protective stepping and, 834-836
  - in nursing home, causes and risk factors for, 883-888
    - diagnostic approach to, 888-891
    - ambulatory cardiac monitor, 890-891
    - circumstances, 889
    - gait and balance assessment, 890
    - laboratory evaluation, 890
    - mobility and independence, 890
    - symptoms, 889-890
  - epidemiology of, 881-883
  - incidence of, 882
  - prevention of, 881-902
  - risk factors for, 884
  - therapy and prevention, 891-899
    - environmental assessment, 894-895
    - improving gait and balance impairments, 893
    - managing polypharmacy/inappropriate medications, 894
    - nursing interventions, 895-896
    - prevention devices and programs, 896-899
    - treating dizziness syndromes, 893
    - treating postural hypotension, 893-894
    - treating weakness and impaired function, 892
  - injurious, characteristics predicting fracture, 750-751

## cohort studies of, 748

- importance as public health problem, 745-746
- prevention of, 752-756
  - assessment and intervention, 753-756
  - physical performance tests, 754
  - primary, 753
  - reduction of, multifactorial approach to, 745-759
    - research findings in, 751-752
  - risk factors for, 746-751
    - characteristics of faller, 747
    - situational, 750
    - treatment of, 755
- medications and, 847-858. *See also Medications.*
- prevention of, creation of supportive environment, 874-878
  - barriers to safety modifications, 875-878
    - affordability, 876
    - installation, 876-877
    - legal, 877-878
    - psychologic, 875-876
    - recognizing need, 875
  - devices for, 896-899
  - environmental press and, 872-873
  - in nursing home, 881-902
  - limitations of research on, 870-871
  - role of environment in, 859-880
- risk of, center of pressure displacement and, 646-647
  - compensatory feet-in-place reactions and, 650-651
  - compensatory stepping reactions and, 652
  - technology-based assessment for, 736-737
    - sequence of actions in, 868
    - technology-based assessment of, 733
- Fallers, in long-term care settings, 867
- Family, definition of, 531-532
  - impact of pain on, 533-534
  - involvement in pain management, 531-547
- Family Pain Questionnaire, 540, 542-543
- Feedback control, definition of, 636
- Feedforward control, definition of, 636
- Feeding, trial of, failure of, 387
- Feet-in-place reactions, compensatory, control of, 650-651
  - effects of aging on, 645-649
- Femur, fracture of, as reason for physician visit, 446
- Fentanyl, as opioid agonist, 493
  - for postoperative pain management, 589
  - transdermal, for cancer pain, 292
- Fibrinogen levels, in atherosclerotic thrombogenesis, 10



- FICSIT, balance measurement with, 713-714  
     for functional balance and gait measures, 718  
     study of falls in, findings in, 752
- Field loss, and mobility, 812
- Filial piety, cultural differences concerning, 399-400
- Financial barriers, to effective palliative care of terminal patients, 411-412
- Fitness, decline with aging, 210-211
- Fluid decrease, in impending death, 363
- Fluoxetine, for depression, in terminal illness, 336
- Fluvoxamine, for depression, in terminal illness, 336-337
- Food choices, in spoon feeding, 386
- Food decrease, in impending death, 363
- Foot, compensatory movements of, control of, 649-653  
     problems with, and risk of fall, treatment of, 755  
     rotation of, kinematics of, 669
- Foot progression, kinematics of, 670
- Force plate, definition of, 636
- Fractures, with falls, cohort studies of, 748  
     risk factors for, 749
- Frail elderly, postoperative pain management in, 583-599  
     analgesics for, 586-594  
     assessment for, 586
- Frailty, definition of, 761
- Fresnel prisms, for hemianopic field defects, 819
- Functional Ambulation Classification, of gait disorders, 690
- Functional impairment, and falls, in nursing home, 887-888
- Functional limitations, definition of, 762
- Functional loss, relationship to physiologic loss, evidence for, 762-763
- Functional performance, exercise to improve, 761-784
- Functional Reach, for functional balance and gait measures, 717
- Futility, definition of, 377  
     in end of life decision making, 374
- Gait. See also *Balance*.  
     changes with aging, 664-665  
     technology-based assessment of, 728-734  
     control of balance during, 653-654  
     data on, young vs old, 674-675  
     definition of, 660-661, 707  
     demands of, methods to increase, 728  
     disorders of, and falls, in nursing home, 885  
     classification system for, 695-698  
     diagnoses in, 693-694  
     differential diagnosis of, 689-703  
     evaluation and treatment of, 696-700  
     in Parkinson's disease, 825-845  
     clinical manifestations of, 825-827  
     laboratory studies of, 835-838  
     in patients referred for neurologic evaluation, 692-695  
     rehabilitation for, 699  
     self-reported, 691-692  
     senile, 695  
     sensorimotor levels in, 695-698  
     efficiency of, young vs old, 675  
     energy transfers during, young vs old, 675  
     functional assessment of, 690-691, 705-723  
     appropriate measures for, 708-710  
     evaluation framework for, 719-720  
     properties and potential uses of, 717-718  
     rationale for, 706-708  
     future work on, 676  
     kinematics of, 665-671  
     kinetics of, 671-673  
     maximal, young vs old, 674-675  
     motor control and balance in, 662-664  
     musculoskeletal changes in, 664  
     neurologic changes in, 662  
     physiologic changes in, 661-662  
     physiology and biomechanics of, effects of age on, 659-678  
     kinematics, 665-671  
     problems with, and risk of fall, treatment of, 755  
     technology-based assessment of, challenges facing, 739  
     simple assessment vs, 737  
     techniques for, 725-744  
     use and misuse of, 737-739  
     velocity and timed measures of, 664-665
- Gait Abnormality Rating Scale, 691, 716
- Gait cycle, definition of, 660  
     events of, 662  
     terminology of, 660
- Gait speed, as measure of mobility, 714-715  
     elements of, 715  
     for functional balance and gait measures, 718  
     functional assessment of, 690-691
- Gastric ulcer, as reason for physician visit, 445
- Gastrostomy, complications of, 381
- Gemfibrozil, as lipid-lowering agent, 37
- Get Up and Go Test, of gait disorders, 690
- Glucose tolerance, and diabetes mellitus, 69-70  
     effect of physical activity on, 80
- Goldman perimetry, for peripheral visual field evaluation, 814-815

- Good-byes, with impending death, 365  
 Gout, as reason for physician visit, 445  
 Grief, following death, 365-367  
   abnormal, 366-367  
   normal, manifestations of, 366  
   signs and symptoms of, 275  
 Ground reaction forces, definition of, 636  
 Group therapy, pain clinic use of, 570  
 Guided imagery, for pain management, in terminal care, 305-306
- Haloperidol, in terminal illness, for anxiety, 332  
   for delirium, 342  
 Head motion, and postural control, 647  
 Headache, as reason for physician visit, 443  
   with nitrate therapy, 124  
 Health, changes with exercise training, 212-213  
   decline with aging, 211  
 Heart disease, ischemic, revascularization in, 203  
   transition to terminal care in, 353-354  
 Heart failure, congestive, in acute myocardial infarction, 153-154  
 Heat, as pain inducer, effects of, 439  
 Heat therapy, in pain management, 520  
 Hemianopia, rehabilitative devices for, 817-820  
 Heparin, for unstable angina, 135  
 Heroin, for cancer pain, 290-291  
 Herpes zoster, as reason for physician visit, 445  
 Heterocyclic antidepressants, for depression, in terminal illness, 338  
 Hip, effect on gait, 673-674  
   fractures of, interventions to decrease, 752  
   with falls, risk factors for, 749  
   gait kinetics of, 672  
   kinematics of, 667-670  
   motion of, and postural control, 648  
 Hirudin, for unstable angina, 136  
 HMG-CoA reductase inhibitor, as lipid-lowering agent, 37  
 Holter monitoring, in myocardial infarction diagnosis, 93-97  
 Home, as death setting, 362  
 Hospice, 417-428  
   approach to suffering by, 239-240  
   as death setting, 362  
   cost-benefit analysis of, 422  
   cost-effectiveness of, 421-425  
     National Hospice Study, 421-424  
     randomized trials, 424-425  
     studies of, 425  
   cost per week of, 423  
   development of, 256-258, 417-418  
   economic principles of, 419-421  
   evolution into twenty-first century, 419  
   goals of, 258  
   in terminal illness, 254, 270  
   interdisciplinary team for, 260-261  
   national and international organizations, 263-264  
   need for in 1990s, 262-263  
   philosophy of, 258-260  
   predicting terminal diagnosis in, 261-262  
   services and structure of, 418-419  
 Hospice Association of America, 264  
 Hospital, as death setting, 362  
 Humerus, fracture of, as reason for physician visit, 446  
 Humphrey visual field test, 814-816  
 Hydration, in terminal patient, 379-391  
   parenteral, sole use of, 387  
 Hydrocodone, as opioid agonist, 492-493  
   for cancer pain, 291  
 Hydromorphone, as opioid agonist, 493  
   for cancer pain, 291  
 Hydroxyzine, for anxiety, in terminal illness, 332  
 Hyperalgesia, with nerve injury, 503  
 Hyperglycemia, tight control of, 74  
 Hypertension, after acute myocardial infarction, management of, 176  
   aging and, cardiac sequelae of, 46  
   common features of, 45  
   and coronary artery disease, 41-56  
   pathophysiologic relationships between, 52  
   and diabetes mellitus, cardiovascular disease risk with, 70-71  
   control of, in diabetes mellitus, 75  
   diagnosis of, 46-47  
   epidemiologic observations, 41-44  
   long-term follow-up, 42-43  
   placebo-controlled therapeutic trials, 43-44  
   essential, cardiac structural adaptation to, 58  
   pathophysiology of, 44-46  
   cardiac sequelae of, 46  
   decreased arterial compliance, 44-46  
   therapy for, 48-53  
   benefit vs hazard of, 48-49  
   extent of, 48-49  
   preferred drug for, 49  
   preventive, 50-53  
 Hypotension, in acute myocardial infarction, management of, 154-155  
   orthostatic, and falls, in nursing home, 886  
   postural, postural dizziness without, 789
- Illumination, with visual field loss, 819-820  
 Impairment, definition of, 762  
 Incontinence, in impending death, 363

- Injury, incidence by age and activity, 219
- Instability, 679-688  
     clinical evaluation of, 680-682  
         biomedical model, 681  
         ecologic model, 682  
         functional model, 681  
         pathophysiologic model, 680  
     consequences for health and function, 679-680  
     in Parkinson's disease, 827  
     management strategies for, 685-687  
         adaptation to irreversible deficits, 686  
         efficacy of interventions, 687  
         multidisciplinary approach, 686-687  
         reduction of deficit burden, 686  
         reversal of deficits, 685-686  
     postural, evaluation of patients with, 682-685  
         context of fall, 683-684  
         diagnostic testing, 685  
         history, 682-683  
         home evaluation, 685  
         performance testing, 684  
         physical examination, 684  
         symptoms, 683  
     technology-based assessment of, 733
- Insulin sensitivity, effect of physical activity on, 80
- International Hospice Institute, 264
- Intestinal colic, in terminal illness, management of, 323
- Inverted pendulum, definition of, 636
- Isolation, in dying process, 360
- Isosorbide-5-mononitrate, for angina, 126
- Isosorbide dinitrate, for angina, 126
- Jejunostomy, complications of, 381
- Jewett hyperextension orthosis, for back pain management, 522, 524
- Jogging, injury during, incidence by age and activity, 219
- Joint, pain in, as reason for physician visit, 444
- Joint kinematics, in frontal plane, 668  
     in sagittal plane, 667  
     in transverse plane, 669  
     of gait, 665
- Joint movement, definition of, 660
- Joint power, definition of, 661  
     sagittal plane kinetics of, 672
- Judgment, substituted, definition of, 376
- Justice, in end of life decision making, 374  
     in pain management, 621
- Karnovsky performance status scale, 352
- Ketamine, for neuropathic pain, 513
- Kinematic measures, of adults, 666
- Kinetics, of gait, 671-673
- Knee, effect on gait, 673
- gait kinetics of, 672  
     kinematics of, 667-668, 670  
     osteoarthritis of, postural control and gait assessment in, 735-736
- Labyrinthitis, and dizziness, 790
- Late stance, kinetics of, 674
- Laxatives, and falls, 852  
     for constipation, in terminal illness, 320
- Left ventricular hypertrophy, 57-68  
     identification of, 58  
     prevention of, 62  
     reduction in, 62-65  
         drug strategies for, 63-65  
         nonpharmacologic modalities in, 63  
     risk factors for, 59  
     sequelae of, 59-62  
         decreased coronary perfusion, 59  
         dysrhythmias, 60-61  
         major cardiac events, 61-62  
         ventricular dysfunction, 61
- Levorphanol, for cancer pain, 292
- Liberty, definition of, 377
- Lidocaine, adjuvant, for cancer pain, 295
- Life, end of, developmental tasks and landmarks for, 248  
     ethical decision making near, 369-377  
     opportunity at, nature of, 237-252  
         developmental model of, 247-249  
         life review, 249-250  
         meaning and the transcendent, 250-251
- Lightheadedness, presyncopal, 786
- Lipid(s), abnormalities of, control of, in diabetes mellitus, 75  
     levels of, effect of physical activity on, 80
- Lipid-lowering agents, 37
- Lipoprotein disorders, as predictors of cardiovascular disease risk, 34-35
- Lipoprotein(a) levels, in atherosclerotic thrombogenesis, 9-10
- Lithium carbonate, for depression, in terminal illness, 340
- Local anesthetic, blocks with, for pain prognosis, 550  
     systemic, for neuropathic pain, 510
- Locomotion, disorders of, in Parkinson's disease, 826
- Long-term care facilities, falls in, incidence of, 882  
     studies of, 866-869  
     supportive, for falls prevention, 874
- Lorazepam, for delirium, in terminal illness, 343
- Low body mass index, and risk of fall, treatment of, 755
- Low vision, definition of, 803
- Lower extremity function test, for functional balance and gait measures, 718

- Lumbar sympathetic block, for pain, 552-553
- Macrophage formation, in atherosclerosis, 3-5
- Macular degeneration, and visual field loss, 806
- Magnesium, for acute myocardial infarction, 151
- Malignant pain, initial management strategies for, 611
- Mass, center of, definition of, 636
- Massage, for pain management, in terminal care, 304-305
- Medications, and falls, 847-858
  - background, 847-848
  - challenges in linking, 853-854
  - confounding by indication, 853-854
  - interventions for, 854
  - possible drugs of concern, 850-853
  - antihypertensive agents, 851-852
  - polypharmacy, 852-853
  - psychoactive agents, 850-851
  - possible mechanisms of, 848-850
  - pharmacodynamics, 849-850
  - pharmacokinetics, 848-849
  - and risk of fall, treatment of, 755
- Memory, with aging, 467
- Meniere's disease, and dizziness, 790
- Meperidine, for cancer pain, 292
  - for postoperative pain management, 589
- Mesenteric infarction, atypical pain in, 441
- Metabolic state, in atherosclerotic thrombogenesis, 9-10
- Methadone, for cancer pain, 292
  - for postoperative pain management, 592
- Methotrimeprazine, in terminal illness, for anxiety, 332
  - for delirium, 343
- Methylphenidate, for depression, in terminal illness, 338
- Metoprolol, after acute myocardial infarction, 170
  - for acute myocardial infarction, 144-145
- Midazolam, for delirium, in terminal illness, 343
- Migraine headache, as reason for physician visit, 443
- Minifier, for peripheral field defects, 817
- Mirrors, for hemianopic field defects, 819
- Mobility, and peripheral visual field defect rehabilitation, 817-819
  - assessment of, reliability of, 711
  - contrast sensitivity and, 806-811
  - dark adaptation and, 811
  - field loss and, 812
  - stereopsis and, 812
  - visual deficits and, 803-823
- Monoamine oxidase inhibitors, for depression, in terminal illness, 339-340
- Monocyte recruitment, in atherosclerosis, 3-5
- Morphine, as opioid agonist, 493
  - for cancer pain, 290
  - structure of, 494
  - unwanted effects of, 496-498
- Mortality, indicators of, 350
- Motor control, in gait, 662-664
- Motor function, assessment of, in dizziness, 797
- Movement, delayed, in Parkinson's disease, 833-834
  - volitional, control of balance during, 653-654
- Multidisciplinary pain clinics, 563-582. See also *Pain clinics*.
- Muscle contraction, definition of, 660
- Musculoskeletal changes, in gait, 664
  - with exercise training, 212
- Musculoskeletal impact, of activities/exercises, 219
- Musculoskeletal pain, initial management strategies for, 611
- Musculoskeletal problems, and risk of fall, treatment of, 755
- Musculoskeletal structure-function, physiologic decline with aging, 209
- Musculoskeletal system, and postural control, effects of aging on, 643-644
- Myocardial infarction, acute, 91-92
  - atypical pain in, 441
  - complications of, 142-143, 153-158
    - arrhythmias, 155-156
    - cardiogenic shock, 157-158
    - conduction disturbances, 155-156
    - congestive heart failure, 153-154
    - hypotension, 154-155
    - myocardial rupture, 156-157
  - diagnostic techniques for, 92-98
  - ambulatory electrocardiography, 93-97
  - echocardiography, 97-98
  - resting electrocardiography, 92-93
  - stress testing, 93
- dyslipidemia after, 175-176
- estrogen replacement after, 177-178
- ethical issues in, 159-160
- hypertension after, 176
- in diabetes mellitus, 73
- management after, 169-180
  - angiotensin-converting enzyme inhibitors for, 172-174
  - anticoagulants, 174-175
  - aspirin, 174
  - beta blockers, 169-171
  - calcium channel blockers, 171-172
  - non-Q-wave, therapy for, 158-159
  - percutaneous transluminal coronary angioplasty for, 187-188
  - risk stratification in, 159
  - silent or unrecognized, incidence of, 91

- smoking after, management of, 176-177  
 stress test following, 105-106  
 therapy for, 141-168  
   angiotensin-converting enzyme inhibitors, 150-151  
   antiarrhythmic agents, 151-152  
   anticoagulants, 149  
   aspirin, 143-144  
   beta blockers, 144-146  
   calcium antagonists, 150  
   coronary angioplasty, 152-153  
   early, 143  
   efficacy of, 160  
   general measures, 142-143  
   general principles, 141-142  
   magnesium, 151  
   nitrates, 149-150  
   thrombolytic therapy, 146-149  
   ventricular arrhythmias after, management of, 177
- Myocardial ischemia, in coronary artery disease, 89-91  
 silent, in myocardial infarction prediction, 94, 96-97  
 with hypertension, 47
- Myocardial rupture, in acute myocardial infarction, 156-157
- Myoclonic movements, with opioids, 497
- Narcotics, for postoperative pain management, 588-594  
   nonparenteral delivery methods for, 589  
   overview of, 588-589  
   parenteral delivery methods for, 589-594  
     intravenous, 589-590  
     patient-controlled anesthesia, 495, 590-591  
     preferred, 593  
     spinal opioids, 591-593  
   regional/local administration of, 593-594  
   neuraxial, for pain, 557-560
- National Cholesterol Education Program, 36
- National Health and Nutrition Survey I Epidemiological Follow-up Study, of pain frequency, 447, 449-451  
 of pain intensity, 452
- National Hospice Organization, 263-264  
 prognosis guidelines of, 352
- Nausea, in terminal illness, causes of, 315  
 management of, 313-316  
 with opioids, 497
- Nerve blocks, for pain management, in terminal care, 308
- Nerves, afferent, damage to, pain with, 503
- Nervous system, and postural control, effects of aging on, 641-643
- Neuraxial narcotics, for pain, 557-560
- Neuroleptics, in terminal illness, for anxiety, 332-333  
 for delirium, 343-344
- Neurologic evaluation, for gait disorders, 692-695
- Neurologic symptoms, in myocardial infarction, 92
- Neurolysis, for pain, 555-556
- Neuronitis, vestibular, and dizziness, 790
- Neuropathic pain, 505-506. See also under *Pain*.
- Neurosensory impairments, and dizziness, 793-794, 796
- Neurostimulation, for pain management, in terminal care, 301-305  
   acupuncture, 303-304  
   massage, 304-305  
   transcutaneous electrical nerve stimulation, 302-303
- New York Heart Association Classification System, 354
- Nicotinic acid, as lipid-lowering agent, 37  
 avoidance of, in diabetes mellitus, 75
- Nifedipine, after acute myocardial infarction, 171  
 for sympathetically maintained pain, 504
- Nightmares, with opioids, 497
- Nitrates, for acute myocardial infarction, 149  
 for angina, 123-126  
 preparations of, 125-127  
 tolerance to, 125
- Nitroglycerin, for unstable angina, 135  
 sublingual, for stable angina, 132  
 transdermal, for angina, 126-127
- NMDA antagonists, for neuropathic pain, 513
- Nociceptive nerve pathway, 502
- Nonmaleficence, in pain management, 621
- Non-opioids, for cancer pain, dosing of, 287
- Nonsteroidal anti-inflammatory drugs, classes of, 286  
 for postoperative pain management, 586-588
- Nonvisceral structures, sympathetically mediated pain in, 550
- Nonvoluntary euthanasia, definition of, 624
- Norepinephrine, for neuropathic pain, 512
- Norfluoxetine, for depression, in terminal illness, 336
- Nortriptyline, for depression, in terminal illness, 335
- Nursing, pain clinic use of, 570-571
- Nursing home, as unique care setting, 606-607  
 falls and fall prevention in, 881-902  
 pain in, 601-614. See also under *Pain*.
- Nutrition, in terminal patient, 379-391

- Obesity, cardiac structural adaptation to, 58
- Obligation, cultural differences concerning, 399-400
- Octreotide, for bowel obstruction, in terminal illness, 324
- Ocutek Image Minifier, for peripheral field defects, 817-818
- Operant conditioning, in pain management, 465
- Opiates, availability and use of, as barriers to effective palliative care, 408-411  
   lack of knowledge, 409-410  
   misconceptions about, 410-411  
   rules and regulations, 408-409
- Opioid(s), agonist, 490, 492-495  
   codeine, 492-493  
   equianalgesic dosing of, 493  
   hydrocodone, 492-493  
   injection of, for pain, 558  
   metabolism and elimination of, 493-495  
   oxycodone, 492-493  
   classification of, 490  
   dosing equivalence of, 289  
   for cancer pain, 288-292  
     adjuvant analgesics with, 294-296  
     agonist-antagonist, 288-289  
     codeine, 291  
     heroin, 290-291  
     hydrocodone, 291  
     hydromorphone, 291  
     levorphanol, 292  
     meperidine, 292  
     methadone, 292  
     morphine, 290  
     oxycodone, 291  
     preparations of, 291  
     propoxyphene, 292  
     pure agonists, 289-290  
     routes of administration of, 293-294  
     side effects of, 292-293  
     tolerance, dependence, and addiction with, 293  
     transdermal fentanyl, 292  
   for dyspnea, in terminal illness, 317-318  
   for neuropathic pain, 506-507  
   in elderly, 489-500  
     beliefs about, 490  
     issues in beginning therapy with, 490-491  
     polyanalgesic pharmacy, 490-491  
     initiating and maintaining therapy with, 496-497  
     short- and long-acting, 290  
     unwanted effects of, 497-498
- Orthotic prescription, in pain management, 521-522
- Osteoarthritis, and pain, 476  
   as reason for physician visit, 444
- Osteoporosis, and compression fracture, 525  
   and risk of fall, treatment of, 755  
   effect of physical activity on, 81
- Oxycodone, as opioid agonist, 492-493  
   for cancer pain, 291
- Oxygen, for dyspnea, in terminal illness, 318  
   for unstable angina, 135
- Pain, and patient request for assisted suicide/euthanasia, 625  
   as reason for physician visit, 442-446  
   atypical presentation of, 441  
   behavioral-cognitive model of, 461-471  
   "break-through," management of, 496  
   causes of, meanings regarding, 618, 620  
   chronic, and old age, 442-453  
   epidemiology of, 442-453  
     pain clinic patients, 447-453  
     survey findings, 442-447  
   in pain clinic patients, frequency of, 449-451  
   intensity of, 452-453  
   prevalence of, 475  
   clinical, 441-442  
   common syndromes of, 524-527  
     compression fracture, 525-526  
     spinal stenosis, 526-527  
   control of, for dying patient, 254  
   definition of, 436-442, 531-532  
   diagnosis and treatment of, invasive modalities for, 549-561  
   dimensions of, 463  
   experience of, caregiver, 537  
     factors in, 462  
     patient, 536  
     patient vs family, 534-536  
   experimentally induced, 437-438  
   family descriptions of, 535  
   frequency and effect of, community dwellers vs institutional residents, 449-451  
   immediate causes of, meanings regarding, 618  
   immediate effects of, meanings regarding, 619  
   impact on quality of life, 533, 612  
   in cognitively impaired older persons, 473-487  
     observational assessment of, 483-484  
     observer ratings of, 481-483  
     self-reports of, validity of, 479-481  
   in nursing home, 601-614  
   and quality of life, 612  
   assessment of, 607-610  
     barriers to, 610  
     depression in, 609-610  
     flow sheet for, 609

- initial, 608
- instruments for, 607
- effects of, self-reported, 605
- interdisciplinary approach to, organization, structure, and relationships in, 606
- management of, barriers to, 604-606
- prevalence of, 603
- scope of problem, 602-604
- sources of, 604
- treatment of, 611-612
- laboratory studies of, 437-440
- localized, perception of, cognitive impairment and, 478
- loss of sensitivity to, 453-454
- management of, barriers to, 281-282, 531-532
  - caregiver roles in, 536-538
  - clinical care in, 621-623
  - comorbidities in, 578
  - costs associated with, 541-543
  - costs to patients and families, 543-545
  - ethical issues in, 615-628
  - factors in, 532
  - family and caregiver involvement in, 531-547
  - implications for family education, 539-541
  - in terminal care, 279-299
  - in uninsured, 543-544
  - meaning from, 616-619
  - noncompliance with, 544
  - nonpharmacologic, in terminal care, 301-311
    - behavior modification, 305-307
    - nerve blocks, 308
    - neurostimulation, 301-305
    - radiation therapy, 309-310
    - specialized techniques, 307-310
    - surgical destruction, 308-309
      - cordotomy, 309
      - dorsal rhizotomy, 309
  - patient conflicts and decisions in, 622-623
  - physical medicine and rehabilitation in, 517-529. See also *Physical medicine/rehabilitation*.
  - postoperative, for frail elderly, 583-599
    - analgesics for, 586-594
    - assessment for, 586
    - factors hindering, 585-586
    - specialized clinics for, 579-581
    - spirituality in, 616
    - undertreatment of, 622
  - meaning of, 618-620
  - multidisciplinary and multidimensional aspects of, 462
  - neuropathic, 505-506
    - analgesics for, 506-513
    - alpha<sub>1</sub> agonists, 512
    - anticonvulsants, 510
    - antidepressants, 507-510
    - antiviral agents, 512-513
    - capsaicin, 511
    - central nervous system depressants, 506-507
    - NMDA antagonists, 513
    - opioids, 506-507
    - systemic local anesthetics, 510
    - topical, 511
  - management of, 506
    - initial strategies for, 611
  - pathways of, 502-503
  - perception of, 435-459
  - postoperative, assessment of, 586
    - effects of, 584
    - experience of, 583-585
    - prevention of, 584
    - therapy for, 584
  - procedural, 441-442
  - prognosis of, local anesthetic blocks for, 550
  - psychologic evaluation of, 464
  - self-reports of, 605
    - validity of, in cognitively impaired persons, 479-481
  - sources of, anatomic localization of, 550
  - sympathetically maintained, 503-505
  - sympathetically mediated, in nonvisceral structures, 550
  - threshold of, 438
  - treatment of, impact of cognition on, 467
    - sympathetic blocks for, 551-555
      - celiac plexus, 553-555
      - lumbar, 552-553
      - stellate ganglion, 551-552
  - types of, 437
  - ultimate cause of, meanings regarding, 620
  - undertreatment of, 482
  - unpleasantness of, effect of age on, 454-455
  - unrelieved, ethical issue of, 282
- Pain clinics, multidisciplinary, 563-582
  - analgesics dispensed by, 567
  - diagnostic categories used by, 575
  - evaluation by, 571-576
  - medical management of, 566-568
  - nursing, 570-571
  - organization of, 564-565
  - patients referred to, 565
    - active medical problems of, 573
    - improvement in, 576
    - previous pain treatment strategies in, 573
    - social profile of, 572
  - pharmacologic management, 567
  - pharmacy, 568
  - physiotherapy, 568-569



- Pain clinics (*continued*)  
 pre- and post-treatment pain, mood, and activity ratings, 577  
 programs in, 565  
 psychology, 569-570  
 psychometric instruments used by, 574  
 team approach, 571  
 specialized, for older people, 579-581
- Palliative care, 269-270  
 effective, barriers to, 407-416  
   availability and use of opiates, 408-411. See also *Opiates*.  
   breaking of, 414-415  
   cultural attitudes toward death and terminal care, 412-414  
   financial, 411-412  
   separation and segregation, 414
- Paraesthesiae, as reason for physician visit, 445
- Parkinson's disease, interventions in, 838-841  
   future studies of, 840-841  
   pharmacologic, 838-839  
   physical, 839-840  
   kinematic studies in, 837-838  
   postural control and gait assessment in, 734-735  
   posture, balance, and gait disorders in, 825-845
- Paroxetine, for depression, in terminal illness, 336-337
- Passive euthanasia, definition of, 624
- Patient, pain experience of, 536
- Patient-controlled analgesia, 495
- Pelvis, fracture of, as reason for physician visit, 446  
   kinematics of, 667-670
- Pemoline, for depression, in terminal illness, 338
- Pendulum, inverted, definition of, 636
- Peptic ulcer, atypical pain in, 441
- Percutaneous endoscopic gastrostomy, tube feeding vs, 386
- Performance-Oriented Balance and Mobility Assessment, for functional balance and gait measures, 717  
   of balance, 690, 710  
   of gait disorders, 690, 710  
   reliability and validity of, 711
- Permission to die, granting of, with impending death, 365
- Perturbation(s), and falls, 638-639  
   definition of, 636  
   of postural control system, 637
- Pharmacodynamics, of medications, and falls, 849-850
- Pharmacokinetics, of medications, and falls, 848-849
- Pharmacologic intervention, in pain management, 520
- Pharmacologic stress testing, 113-114  
   for myocardial infarction diagnosis, 93
- Pharmacy, of pain clinic, 568
- Phenol neurolysis, for pain, 556
- Physical activity, changes with aging, 81-82  
   for coronary heart disease prevention, recommendations for, 82-84  
   guidelines for older individuals, 84-85  
   health benefits of, 79-80  
   in coronary heart disease, effect on other risk factors, 80-81  
   lack of, and coronary heart disease, 79-88
- Physical deconditioning, and dizziness, 792-793
- Physical medicine/rehabilitation, in pain management, 517-529  
   interdisciplinary assessment, 518-519  
   interdisciplinary case management conference, 519-520  
   pharmacologic intervention, 520  
   physical modalities, 520-524  
   anesthetic procedures, 522-523  
   cognitive-behavioral therapies, 523-524  
   heat, 520  
   orthotic prescription, 521-522  
   progressive exercise, 522  
   transcutaneous electrical nerve stimulation, 521  
   team approach to, 517-524
- Physical modalities, in pain management, 520-524
- Physiologic decline with aging, and cardiac disease, 208-211
- Physiologic loss, relationship to functional loss, evidence for, 762-763
- Physiologic performance, exercise to improve, 761-784
- Physiotherapy, pain clinic use of, 568-569
- Plantar cutaneous pressure sensation, facilitation of, effect of, 642
- Platelet activity, enhanced, in atherosclerotic thrombogenesis, 10
- Polypharmacy, and falls, 852-853
- Poor vision, and risk of fall, treatment of, 755
- Positional vertigo, and dizziness, 789-790
- Post-stroke central pain, 505
- Postural adjustments, for balance, 706-707
- Postural control, 635-658  
   and falling, 635-640  
   demands of, methods to increase, 728  
   feedback, definition of, 636  
   feedforward, definition of, 636  
   substrates of, effects of aging on, 640-644  
   musculoskeletal system, 643-644  
   nervous system, 641-643  
   sensory systems, 640-641  
   system of, conceptual model of, 637

- technical terms involving, 636
- technology-based assessment of, challenges facing, 739
  - changes with aging, 728-734
  - simple assessment vs, 737
  - techniques for, 725-744
  - use and misuse of, 737-739
- Postural hypotension, postural dizziness without, 789
- Postural performance, effects of aging on, 644-654
  - control of balance during gait and volitional movement, 653-654
  - control of compensatory arm movements, 649-653
  - control of compensatory feet-in-place reactions, 645-649
  - control of compensatory foot movements, 649-653
  - control of unperturbed stance, 644-647
- Posture, disorders of, in Parkinson's disease, 825-845
  - clinical manifestations of, 825-827
  - laboratory studies of, 828-838
  - perturbation of, laboratory study of, 832
- Posturography, dynamic, for postural control and gait assessment, 729
- Precordial pain, as reason for physician visit, 444
- Presbyalgos, definition of, development of, 453-455
  - possible characteristics of, 456
- Presbyastasis, 788
- Pressure, as pain inducer, effects of, 439
  - center of, definition of, 636
- Presyncopal lightheadedness, 786
- Primary care, in terminal illness, 268-269
- Primary care physician, role in care of terminally ill, 267-278
  - references for, 268
- Prisms, for hemianopic field defects, 818-819
- Privacy, definition of, 377
- Propoxyphene, for cancer pain, 292
- Propranolol, after acute myocardial infarction, 170
  - for acute myocardial infarction, 145
- Protriptyline, for depression, in terminal illness, 335
- Proxy, definition of, 376
- Pseudothalamic pain, 505
- Psychiatric symptoms, in terminal care, management of, 329-348
- Psychoactive agents, and falls, 850-851
- Psychological evaluation, of elderly pain patient, 464
- Psychological factors, and dizziness, 794
- Psychological status, assessment of, in dizziness, 797
- Psychology, pain clinic use of, 569-570
- Psychometric instruments, nursing home use of, 607
  - pain clinic use of, 574
- Psychostimulants, for depression, in terminal illness, 338-339
- PTCA, 181-194. See also *Coronary angioplasty*.
- Pulmonary disease, transition to terminal care in, 355-356
- Pulmonary structure-function, physiologic decline with aging, 209
- Quality of death, in hospice care, 423
- Quality of life, impact of pain on, 533
  - in nursing home, outcome measures of, 612
- Radiation therapy, for pain management, in terminal care, 279, 309-310
- Radionuclide exercise testing, diagnostic utility of, 109-110
  - prognostic utility of, 110-113
- Ramipril, after acute myocardial infarction, 173
- Reflex sympathetic dystrophy, as sympathetically maintained pain, 504
- Relaxation therapy, for pain management, in terminal care, 306
- Reliability, of gait and balance assessment measures, 708-709
- Renal failure, transition to terminal care in, 356
- Resistance exercise training, 220
- Respiratory depression, with narcotics, 588
- Responsiveness, of gait and balance assessment measures, 709-710
- Restlessness, in impending death, 364
- Restraint reduction, total quality management system for, algorithm for, 898
- Revascularization, for unstable angina, 136
- Rheumatism, as reason for physician visit, 444
- Rheumatoid arthritis, as reason for physician visit, 444
- Rib fracture, as reason for physician visit, 446
- Sedation, induction of, for cancer pain, 296
- Segregation, as barrier to effective palliative care, 414
- Self determination, abrogation of, 371
- Sensorimotor levels, in gait disorders, 695-698
- Sensory systems, and postural control, effects of aging on, 640-641
- Separation, as barrier to effective palliative care, 414
- Serotonin reuptake inhibitors, for depression, in terminal illness, 336

- Sertraline, for depression, in terminal illness, 336-337
- Sleeping, in impending death, 363
- Smoking, after acute myocardial infarction, management of, 176-177
- and coronary artery disease, 23-32
- risk factor for, 24-27
- cessation of, benefits in elderly, 27
- in diabetes mellitus, 75
- intervention in, 27-30
- physician impact on, 29
- changing trends in, 27-30
- decline in, 28-29
- pathologic effects on heart, 24
- Smooth muscle cell proliferation, in atherosclerosis, 5
- Socialization, decreased, with impending death, 365
- Somnolence, with opioids, 497
- Spinal cord, electrical stimulation of, for pain, 556-557
- Spinal drug delivery, for pain, 558
- of analgesia, 495
- Spinal fracture, as reason for physician visit, 446
- Spinal stenosis, pain syndrome in, 526-527
- Spirituality, and meaning of pain, 616
- Stability, definition of, 636
- Stairs, falls on, studies of, 865
- Stance, external disturbances of, in Parkinson's disease, corrective responses to, 829-830
- laboratory studies of, 828-833
- protective responses to, 831-833
- maintenance of, technology-based assessment of, 733
- perturbed, studies of, young vs old, 730-731
- unperturbed, control of, age-related changes in, 648
- effects of aging on, 644-647
- in Parkinson's disease, laboratory studies of, 828
- Static, definition of, 636
- Stellate ganglion block, for pain, 551-552
- Step length, definition of, 660
- Step taking, perturbed, studies of, young vs old, 732
- Stepping reactions, compensatory, control of, 650-651
- Stereopsis, and mobility, 812
- Strength, loss of, and performance limitations, 763
- Strength training, interventions and outcomes with, 765-767
- in impaired elders, 768
- studies of, 763-769
- Streptokinase, for acute myocardial infarction, 147-148
- Stress inoculation, in pain management, 466
- Stress testing, diagnostic value of, 103-104
- for coronary artery disease, 101-119
- for myocardial infarction diagnosis, 93
- in stable coronary artery disease, 106-107
- pharmacologic, 113-114
- post-myocardial infarction, 105-106
- protocol for, 104-105
- screening, in asymptomatic individuals, 107-109
- Stride length, definition of, 660
- reduced, in Parkinson's disease, 837
- Stride width, definition of, 660
- Stroke, and dizziness, 791-792
- postural control and gait assessment in, 735
- with left ventricular hypertrophy, 62
- Study of Accidental Falls in the Elderly, findings in, 751
- Substituted judgment, definition of, 376
- Suffering, nature of, 237-252
- pain vs, 462
- philosophy of, 238-244
- clinical response among dying, 242-244
- hospice approach, 239-240
- nature of, 241-242
- personhood, 240-241
- spiritual orientations toward, 238
- symptom management in, 243
- Suicide, assisted, definition of, 624
- moral issues of, 625-626
- pain-related, 623-626
- patient requests for, 624-625
- pain-related, 464, 623-626
- Support, base of, definition of, 636
- Surgical destruction, for pain management, in terminal care, 308-309
- Surrogate, decision making by, near end of life, 373
- definition of, 376
- Swallowing, evaluation of, 386
- Sway, changes with aging, technology-based assessment of, 729
- Sympathetic blockade, for sympathetically maintained pain, 504
- Symptom management, non-pain, in terminal care, 313-327
- SynchroMed programmable infusion system, for patient-controlled anesthesia, 559-560
- Syncope, and falls, in nursing home, 887
- Technology, and changes in cultural context of death and dying, 401
- Technology-based assessment, of postural control and gait, 725-744
- challenges facing, 739

- for fall risk, 736-737
- general issues in, 725-728
  - electromyography, 727
  - gait energetics, 727
  - kinematics, 726
  - kinetics, 727
- in disease-based deficits, cerebrovascular disease (stroke), 735
  - knee osteoarthritis, 735-736
  - Parkinson's disease, 734-735
- in exercise programs, 736-737
- simple assessment vs, 737
- to understand and monitor disease-based deficits, 734-736
- to understand changes with aging, 728-734
- use and misuse of, 737-739
- Telescope, reversed, for peripheral field defects, 817
- Tension headache, as reason for physician visit, 443
- Terminal care, comprehensive, 270-277
  - bereavement care, 273-277. See also *Bereavement care.*
  - care at time of death, 273
  - pain and symptom management, 272
  - psychosocial support, 272-273
  - shift from curative to palliative care, 270-271
- for non-cancer patients, 349-358
  - establishing prognosis in, 350-351
- hospice, 270
- palliative, 269-270
  - barriers to, 407-416. See also under *Palliative care.*
- primary, 268-269
- transition to, 351-356
  - impaired functional status, 351-353
  - impaired nutritional status, 353
  - in dementia, 354-355
  - in heart disease, 353-354
  - in pulmonary disease, 355-356
  - in renal failure, 355-356
- Terminal illness, effective pain management in, 279-299
  - non-pain symptom management in, 313-327
  - nonpharmacologic pain management in, 301-311
  - nutrition and hydration in, 379-391
  - patient desires in, 269
  - predicting diagnosis in, 261-262
  - psychiatric symptoms in, management of, 329-348
  - role of primary care physician in, 267-278
- Thalamic pain, 505
- Thallium scintigraphy, prognostic utility of, 111-112
- Therapeutic privilege, definition of, 377
- in end of life decision making, 371-372
- Thought patterns, in pain management, 465
- Thrombolytic therapy, for acute myocardial infarction, 146-149
  - mortality in, 147-148
- Timed Up and Go Test, for functional balance and gait measures, 716-718
- Timolol, after acute myocardial infarction, 170
  - for acute myocardial infarction, 145
- Tissue plasminogen activator (t-PA), for acute myocardial infarction, 147-148
- Torso, kinematics of, 670
- Tramadol, for cancer pain, 288
- Transcutaneous electrical nerve stimulation, for pain management, in terminal care, 302-303
  - in pain management, 521
  - pain clinic use of, 568
- Transfer function, definition of, 636
- Transient ischemic attacks, vertebrobasilar, and dizziness, 791
- Trazodone, for depression, in terminal illness, 338
- Treatment, decisions to limit, cultural factors in, 401-402
- Tricyclic antidepressants, for depression, in terminal illness, 334-336
  - for neuropathic pain, 507-510
- Tube feeding, complications of, 381
  - in terminal patient, 379
  - long-term, alternatives to, 385-387
  - medical myths about, 380-385
  - aspiration pneumonia, 382-384
  - ordinary care, 380-381
  - painful death, 385
  - swallowing evaluations, 384-385
- Unconsciousness, induction of, for cancer pain, 296
- Urine output decrease, in impending death, 363-364
- Validity, of gait and balance assessment measures, 708-709
- Vasospasm, role of, in coronary plaque evolution, 12-13
- Venlafaxine, for depression, in terminal illness, 337
  - for neuropathic pain, 507-508
- Ventricular arrhythmias, after acute myocardial infarction, management of, 177
- Ventricular dysfunction, with left ventricular hypertrophy, 61
- Ventriculography, prognostic utility of, 112
- Veracity, in pain management, 621
- Verapamil, after acute myocardial infarction, 171
  - for angina, 132

- Vertigo, clinical classification of, 787
    - definition of, 786
    - positional, and dizziness, 789-790
  - Vessel walls, lipid accumulation in atherosclerosis, 3
  - Vestibular neuronitis, and dizziness, 790
  - Vestibulopathy, recurrent, 790
  - Vision, low, and risk of fall, 755
    - definition of, 803
  - Vision contrast test system, 810
  - Vision-like experiences, with impending death, 364-365
  - Visual deficits, and mobility, 803-823
    - continuum of, 806
    - disability with, 804
    - severe, estimated prevalence of, 805
    - training for patients with, 820
  - Visual field(s), evaluation of, 812-816
    - confrontation tests, 813
    - loss of, 804-806
      - conditions causing, 804
      - effect of, 803
        - examples of, 808
        - peripheral defects of, rehabilitation of, 817-819
- Volitional movement, control of balance during, 653-654
  - disorders of, in Parkinson's disease, 833-835
- Vomiting, in terminal illness, causes of, 315
  - management of, 313-316
- Walking, impairment of, in Parkinson's disease, 836
  - injury during, incidence by age and activity, 219
  - studies of, young vs old, 732
- Weakness, and falls, in nursing home, 885
- Williams orthosis, for back pain management, 522-523
- Withdrawal, with impending death, 364
- Zofenopril, after acute myocardial infarction, 173

